Search results for "antico"

showing 10 items of 736 documents

Functional properties of the brain during sleep under subchronic zopiclone administration in man.

1994

Zopiclone, a non-benzodiazepine, has been shown to be efficient in the treatment of transient, short-term or chronic sleep disorders. Apart from its hypnotic effects zopiclone has anxiolytic, anticonvulsant and myorelaxant properties and is therefore hardly distinguishable from benzodiazepines. Dependence liability and discontinuation effects have been reported to be less pronounced. Therefore zopiclone seems to be a hypnotic drug which may cause fewer side effects than conventional benzodiazepines. From the electrophysiological point of view one requires from a hypnotic drug the induction of a physiological sleep pattern as well as no alterations of information processing by the brain. The…

AdultMalemedicine.drug_classmedicine.medical_treatmentPolysomnographyStimulationPolysomnographyAnxiolyticPiperazinesMental ProcessesmedicineHumansHypnotics and SedativesPharmacology (medical)Biological PsychiatryPharmacologyZopicloneSleep Stagesmedicine.diagnostic_testBrainElectroencephalographySleep in non-human animalsPsychiatry and Mental healthElectrophysiologyAnticonvulsantNeurologyAnesthesiaEvoked Potentials AuditoryEvoked Potentials VisualNeurology (clinical)Sleep StagesPsychologySleepNeuroscienceAzabicyclo Compoundsmedicine.drugEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Auditory event-related potentials (P300) in epileptic patients.

2001

Auditory event-related potentials (AERPs) were recorded during an auditory oddball paradigm in 108 epileptics and in 32 healthy controls. P300 latency varied in relationship with age only in controls. Symptomatic epileptics had significantly prolonged P300 mean latency compared to those without detectable brain lesion(s) on MR scan. Moreover, these latter patients were compared on the basis of epilepsy duration, type of seizure, seizure frequency and antiepileptic treatment; the application of a multiple regression model showed a significant relationship between P300 latency prolongation and epilepsy duration, seizure frequency and polytherapy.

AdultMalemedicine.medical_specialtyAdolescentAuditory eventAuditory oddballAudiologyCentral nervous system diseaseEpilepsyCognitionEvent-related potentialSeizuresPhysiology (medical)medicineHumansLatency (engineering)ChildAgedSeizure frequencyEpilepsyGeneral MedicineMiddle Agedmedicine.diseaseEvent-Related Potentials P300NeurologyEvoked Potentials AuditoryBrain lesionsRegression AnalysisAnticonvulsantsFemaleNeurology (clinical)PsychologyNeurophysiologie clinique = Clinical neurophysiology
researchProduct

Deferment of Objective Assessment of Deep Vein Thrombosis and Pulmonary Embolism Without Increased Risk of Thrombosis

2004

Background: Treatment of patients with suspected deep vein thrombosis (DVT) or pulmonary embolism (PE) is problematic if diagnostic imaging is not immediately available. Pretest clinical probability (PCP) and D-dimer assessment can be used to identify patients for whom empirical protective anticoagulation is indicated. To evaluate whether PCP and D-dimer assessment, together with the use of low-molecular-weight heparins (LMWHs), allow objective appraisal of DVT and PE to be deferred for up to 72 hours, patients with suspected DVT and PE were prospectively examined. Methods: Patients identified with a high PCP or a moderate PCP with positive D-dimer test results received a protective full-do…

AdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classDeep veinLow molecular weight heparinFibrin Fibrinogen Degradation ProductsD-dimerInternal MedicinemedicineHumansRisk factoranticoagulationAgedAged 80 and overVenous ThrombosisPatientVascular diseasebusiness.industrylow molecular weight heparinAnticoagulantdeep vein thrombosisuspected PEHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisSurgeryPulmonary embolismmedicine.anatomical_structureD dimerFemalePulmonary EmbolismbusinessAlgorithmsFollow-Up StudiesArchives of Internal Medicine
researchProduct

Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study.

2012

Summary.  Background:  Little information is available on the long-term clinical outcome of cerebral vein thrombosis (CVT). Objectives and methods:  In an international, retrospective cohort study, we assessed the long-term rates of mortality, residual disability and recurrent venous thromboembolism (VTE) in a cohort of patients with a first CVT episode. Results:  Seven hundred and six patients (73.7% females) with CVT were included. Patients were followed for a total of 3171 patient-years. Median follow-up was 40 months (range 6, 297 months). At the end of follow-up, 20 patients had died (2.8%). The outcome was generally good: 89.1% of patients had a complete recovery (modified Rankin Scor…

AdultMalemedicine.medical_specialtyAnticoagulant treatment; Cerebral vein thrombosis; Mortality; Recurrence; Adult; Cerebral Veins; Cohort Studies; Female; Humans; Male; Middle Aged; Recurrence; ThrombosisCohort StudiesAnticoagulant treatment; Cerebral vein thrombosis; Mortality; RecurrenceRecurrenceInternal medicinemedicineRisk of mortalityHumansMED/41 - ANESTESIOLOGIAMortalitybusiness.industryIncidence (epidemiology)Cerebral Vein thrombosiHazard ratioCerebral VeinRetrospective cohort studyThrombosisHematologyMiddle Agedmedicine.diseaseThrombosisCerebral VeinsConfidence intervalSurgerycerebral vein thrombosisSettore MED/15 - MALATTIE DEL SANGUEThrombosiCohortFemaleAnticoagulant treatmentCohort StudiebusinessHumanCohort studyJournal of thrombosis and haemostasis : JTH
researchProduct

A case of atypical sporadic hemiplegic migraine associated with PFO and hypoplasia of vertebro-basilar system.

2009

We describe the case of a patient with atypical hemiplegic migraine and associated basilar symptoms, where a large patent foramen ovale (PFO) and hypoplasia of basilar artery were found. The longer period of 4-year remission of the headache attacks was coincident with the percutaneous PFO closure. When 5 years after, hemiplegic migraine attacks relapsed, with more relevant basilar symptoms, a mild re-opening of PFO was found. The atypical presentation of attacks with basilar symptoms and prolonged hemiplegia does not strictly fit the diagnostic criteria of ICHD-II.

AdultMalemedicine.medical_specialtyAuraMigraine with AuraClinical NeurologyForamen Ovale PatentHemiplegiaCase ReportNeurological disorderHemiplegic migraineRecurrencePFOmedicine.arteryBasilar arteryVertebrobasilar InsufficiencyMedicineHumansCardiac Surgical ProceduresBasilar type migrainebusiness.industryBasilar-Type MigraineAnticoagulantsBrainGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingHypoplasiaMigraine with auraSurgeryAnesthesiology and Pain MedicineTreatment OutcomeVertebro-basilar system hypoplasiaMigraineBasilar ArteryPatent foramen ovalecardiovascular systemNeurology (clinical)sense organsmedicine.symptombusinessTomography X-Ray ComputedMagnetic Resonance AngiographyThe journal of headache and pain
researchProduct

Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular weight heparin.

2009

Introduction: We tested the efficacy and safety of fixed doses of Low-Molecular Weight Heparin (LMWH) in patients requiring interruption of Vitamin-k Antagonist (VKA) because of invasive procedures Methodology: Pre-operatively, patients discontinued VKA 5 +/- 1days; in those at low-risk for thrombosis, LMWH was given at a prophylactic dosage of 3.800 U.I. (nadroparin) or 4.000 U.I. (enoxaparin) anti-FXa once daily the night before the procedure. In patients at high-risk for thrombosis, LMWH was started early after VKA cessation and given at fixed sub-therapeutic doses (3.800 or 4.000 UI anti-FXa twice daily) until surgery. Post-operatively, LMWH was reinitiated 12 hours after procedure whil…

AdultMalemedicine.medical_specialtyBridging low molecular weight heparinTime FactorsVitamin Kmedicine.drug_classLow molecular weight heparinAdministration OralPostoperative HemorrhageRisk AssessmentDrug Administration ScheduleSettore MED/15 - Malattie Del SangueRisk FactorsThromboembolismmedicineHumansProspective StudiesEnoxaparinProspective cohort studyAgedAged 80 and overbusiness.industryIncidence (epidemiology)WarfarinAnticoagulantsNadroparinHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisConfidence intervalSurgeryLow Molecular Weight Heparin Fixed doses Chronic oral anticoagulation perioperative bridgingAnesthesiaSurgical Procedures OperativeNadroparinFeasibility StudiesFemaleWarfarinbusinessmedicine.drugFactor Xa Inhibitors
researchProduct

Home parenteral nutrition-associated thromboembolic and bleeding events: results of a cohort study of 236 individuals

2016

UNLABELLED Essentials Sparse or outdated studies focus on thrombotic and bleeding risk in home parenteral nutrition (HPN). 236 HPN patients followed at a single center for a total of 684 patient-years were evaluated. Rates of venous thrombosis and major bleeding, and prevalence of vena cava syndrome are provided. Anticoagulants might reduce thrombosis risk, but population-specific safety concerns remain. SUMMARY Background Home parenteral nutrition (HPN) is necessary for patients with intestinal failure. Recurrent catheter-related thrombosis (CRT) is common, leading to infectious complications, pulmonary embolism, vascular access loss and intestinal transplantation. The efficacy and safety …

AdultMalemedicine.medical_specialtyCatheterization Central VenousSuperior Vena Cava SyndromeHemorrhage030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineThromboembolismmedicineHumans030212 general & internal medicineProportional Hazards ModelsRetrospective Studiesbusiness.industryHeparinHazard ratioAnticoagulantsRetrospective cohort studyThrombosisHematologyVenous ThromboembolismMiddle Agedmedicine.diseaseThrombosisThrombocytopeniaPulmonary embolismSurgeryTransplantationVenous thrombosisParenteral nutritionTreatment OutcomeFemalebusinessParenteral Nutrition HomePulmonary EmbolismCohort study
researchProduct

Thromboembolic complications of COVID-19: the combined effect of a pro-coagulant pattern and an endothelial thrombo-inflammatory syndrome.

2020

Coronavirus disease 2019 (COVID-19) is a newly emerging human infectious disease that has quickly become a worldwide threat to health, mainly causing severe acute respiratory syndrome. In addition to the widely described respiratory syndrome, COVID-19 may cause life-treating complications directly or indirectly related to this infection. Among these, thrombotic complications have emerged as an important issue in patients with COVID-19 infection, particularly in patients in intensive care units. Thrombotic complications due to COVID-19 are likely to occur due to a pro-coagulant pattern encountered in some of these patients or to a progressive endothelial thrombo-inflammatory syndrome causing…

AdultMalemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Pneumonia ViralDiseaseThromboembolic complicationsCOVID-19 CT ComplicationsSevere Acute Respiratory SyndromeCommunicable Diseases EmergingArticle030218 nuclear medicine & medical imagingBrain IschemiaThromboplastin03 medical and health sciences0302 clinical medicineIntensive careCause of DeathThromboembolismmedicineHumansRadiology Nuclear Medicine and imagingIn patientClinical significanceIntensive care medicinePandemicsAgedbusiness.industrypandemicAnticoagulantsCOVID-19General MedicineMiddle AgedstrokeSurvival AnalysisItalyRadiology Nuclear Medicine and imagingInfectious disease (medical specialty)030220 oncology & carcinogenesisFemaleRadiography ThoracicbusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaCoronavirus InfectionsPulmonary EmbolismTomography X-Ray ComputedThrombotic complicationClinical radiology
researchProduct

Use of gabapentin to reduce chronic neuropathic pain in Fabry disease.

2003

The effect of the anticonvulsant gabapentin on neuropathic pain was studied in six male patients with Fabry disease, aged 15-45 years. After 4 weeks of treatment, pain, as measured using the Brief Pain Inventory, was decreased compared with baseline. Treatment was generally well tolerated. This study indicates that gabapentin should be considered as a treatment option for the neuropathic pain of Fabry disease.

AdultMalemedicine.medical_specialtyDiabetic neuropathyGabapentinAdolescentCyclohexanecarboxylic Acidsmedicine.medical_treatmentAcetatesGeneticsmedicineHumansBrief Pain InventoryAminesGenetics (clinical)gamma-Aminobutyric AcidPain Measurementbusiness.industryVascular diseaseEnzyme replacement therapymedicine.diseaseFabry diseaseSurgeryAnticonvulsantTreatment OutcomeAnesthesiaNeuropathic painFabry DiseaseNeuralgiaAnticonvulsantsGabapentinbusinessmedicine.drugJournal of inherited metabolic disease
researchProduct

Non-fatal and fatal liver failure associated with valproic acid.

2012

Little is known about hepatotoxicity associated with valproic acid (VPA), a widely used substance in neuropsychiatry.All reported cases to the German Federal Institute for Drugs and Medical Devices between 1993 and 2009 of VPA-induced serious hepatic side effects were evaluated.A total of 132 cases of serious VPA-associated liver failure were identified. Approximately one third (34.8%) occurred under VPA monotherapy, while the majority was seen with VPA plus co-medication, most frequently antiepileptics (34.8%) and benzodiazepines (16.7%). A subgroup of 34 cases (25.8%) had a fatal outcome, the largest number reported to date. Of these, 32.4% were under VPA monotherapy and 67.6% under VPA p…

AdultMalemedicine.medical_specialtyFatal outcomeAdolescentGastroenterologyBenzodiazepinesPharmacovigilancePharmacotherapyInternal medicineGermanyPharmacovigilancemedicineHumansPharmacology (medical)ChildAgedAged 80 and overValproic Acidbusiness.industryValproic AcidLiver failureInfantGeneral MedicineMiddle AgedPsychiatry and Mental healthAnesthesiaConcomitantChild Preschoollipids (amino acids peptides and proteins)AnticonvulsantsDrug Therapy CombinationFemaleChemical and Drug Induced Liver Injurybusinessmedicine.drugPharmacopsychiatry
researchProduct